XBiotech USA, Inc. (XBIT)

Oncology Corporate Profile

Stock Performance

18.0900
0.0000

HQ Location

8201 E Riverside Dr 
Bldg 4 Ste. 100
Austin, TX 78744

Company Description

XBiotech is leading the commercialization of biological therapies, including the discovery and development of True Human™ antibodies. The Company’s lead product candidate—now in two unique Phase III registration studies—represents a novel, breakthrough treatment for advanced colorectal cancer. XBiotech has also developed manufacturing technology to reduce infrastructure needs, lessen capital requirements and shorten lead times for development of biological drugs. New manufacturing technologies are at the heart of XBiotech’s approach to next generation biological therapies, including the production of highly competitive biosimilar or biobetter products.

Website: http://www.xbiotech.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Xilonix_monoclonal (IgG1k) antibodyCancer cachexiaIII
Xilonix_monoclonal (IgG1k) antibodyColorectal cancerIII
Xilonix_monoclonal (IgG1k) antibodyNon Small Cell Lung Cancer (NSCLC)II

View additional information on product candidates here »

Pipeline image

Source


http://www.xbiotech.com

Recent News Headlines

XBiotech Announces On-Time Submission to the EMA

3/27/2017 05:02 pm

[GlobeNewswire] - AUSTIN, Texas, March 27, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that it completed on time and confirmed receipt of its March 22, 2017 submission of responses to the remaining ...

XBiotech Announces On-Time Submission to the EMA

3/27/2017 05:01 pm

[GlobeNewswire] - AUSTIN, Texas, March 27, 2017-- XBiotech Inc. announced today that it completed on time and confirmed receipt of its March 22, 2017 submission of responses to the remaining EMA queries related to its marketing ...

XBIOTECH INC. Financials

3/23/2017 05:00 pm

XBiotech Announces Addition of Dr. Dirk Arnold to its Scientific Advisory Board

3/23/2017 12:00 pm

[GlobeNewswire] - AUSTIN, Texas, March 23, 2017-- XBiotech Inc. announced today that that Dr. Dirk Arnold, a leading international specialist in gastrointestinal cancers, has joined the Company’ s Scientific Advisory Board. ...

XBiotech Announces Addition of Dr. Dirk Arnold to its Scientific Advisory Board

3/23/2017 12:00 pm

[GlobeNewswire] - AUSTIN, Texas, March 23, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that that Dr. Dirk Arnold, a leading international specialist in gastrointestinal (GI) cancers, has joined ...

XBiotech to Provide Fourth Quarter and Full Year 2016 Business Update

3/9/2017 01:00 pm

[GlobeNewswire] - AUSTIN, Texas, March 09, 2017-- XBiotech Inc. announced today it will host a conference call and live audio webcast on Thursday, March 16, 2017, at 8:30 a.m. Eastern Time, to provide an overview of its ...

XBiotech to Provide Fourth Quarter and Full Year 2016 Business Update

3/9/2017 01:00 pm

[GlobeNewswire] - AUSTIN, Texas, March 09, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today it will host a conference call and live audio webcast on Thursday, March 16, 2017, at 8:30 a.m. Eastern Time, ...

XBiotech Announces Registered Direct Offering of Common Shares

3/3/2017 02:02 pm

[GlobeNewswire] - AUSTIN, Texas, March 03, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced that it has entered into definitive agreements to sell an aggregate of approximately US$31,000,000 of common ...

XBiotech Announces Registered Direct Offering of Common Shares

3/3/2017 02:01 pm

[GlobeNewswire] - AUSTIN, Texas, March 03, 2017-- XBiotech Inc. today announced that it has entered into definitive agreements to sell an aggregate of approximately US $31,000,000 of common shares in a registered direct ...

XBiotech Completes Dosing of Subjects in PK Study Being Conducted in Connection with European Marketing Application

2/22/2017 01:00 pm

[GlobeNewswire] - AUSTIN, Texas, Feb. 22, 2017-- XBiotech Inc. announced that all subjects have been dosed in its pharmacokinetic study evaluating MABp1 half-life in healthy volunteers. This Phase I study will provide further ...

XBiotech Completes Dosing of Subjects in PK Study Being Conducted in Connection with European Marketing Application

2/22/2017 01:00 pm

[GlobeNewswire] - AUSTIN, Texas, Feb. 22, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced that all subjects have been dosed in its pharmacokinetic (PK) study evaluating MABp1 half-life in healthy volunteers. ...

XBiotech Reports Affirmative Interim Analysis of Global Phase 3 Colorectal Cancer Study

2/21/2017 01:00 pm

[GlobeNewswire] - AUSTIN, Texas, Feb. 21, 2017-- XBiotech Inc. today announced that an Independent Data Monitoring Committee has performed a prospectively planned, unblinded analysis of the Phase 3 XCITE study for the Company’ ...

XBiotech Reports Affirmative Interim Analysis of Global Phase 3 Colorectal Cancer Study

2/21/2017 01:00 pm

[GlobeNewswire] - Unblinded IDMC Review Recommends Continuation of Study AUSTIN, Texas, Feb. 21, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced that an Independent Data Monitoring Committee (IDMC) ...

XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa (HS)

2/16/2017 04:03 pm

[GlobeNewswire] - Results Demonstrate Efficacy of MABp1 as a Treatment for HS AUSTIN, Texas, Feb. 16, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human(TM) therapeutic antibodies, ...

XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa (HS)

2/16/2017 04:01 pm

[GlobeNewswire] - AUSTIN, Texas, Feb. 16, 2017-- XBiotech Inc., developer of next-generation True Human™ therapeutic antibodies, today announced topline results from an investigator sponsored randomized Phase 2 study evaluating ...

XBiotech Phase 3 Data for Colorectal Cancer Therapy is Published in The Lancet Oncology

1/17/2017 01:00 pm

[GlobeNewswire] - AUSTIN, Texas, Jan. 17, 2017-- XBiotech Inc. today announced the publication of results from its pivotal phase 3 trial of the Company’ s lead monoclonal antibody therapy. The results were published in ...

XBiotech Phase 3 Data for Colorectal Cancer Therapy is Published in The Lancet Oncology

1/17/2017 01:00 pm

[GlobeNewswire] - Report Highlights Efficacy of New Antibody Therapy in Advanced Colorectal Cancer AUSTIN, Texas, Jan. 17, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today announced the publication of results ...